Tech Company Financing Transactions
Remedium Bio Funding Round
Remedium Bio, based in Needham, secured $10 million from LifeSpan Vision Ventures and Eli Lilly and Company.
Transaction Overview
Company Name
Announced On
8/10/2026
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series A
Investors
LifeSpan Vision Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the advancement of its lead programs, the continued expansion of its platform technologies, and preparation for first-in-human clinical studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1116 Great Plain Ave 203
Needham, MA 02492
USA
Needham, MA 02492
USA
Phone
Website
Email Address
Overview
Remedium Bio is a Boston based gene therapy company focused on the development of highly innovative treatments for a broad range of diseases. The Remedium approach utilizes proven scientific fundamentals, in a novel way, to treat the most debilitating conditions. Starting with well-characterized pathophysiological principles, our scientists modularly apply proven technologies to quickly advance curative treatments through the R&D cycle. Today, our leading candidates include gene therapy treatments in the fields of Endocrinology, Cardiology, Hematology, and Rheumatology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Francesco Luppino
Chief Operating Officer
Alex Goraltchouk
Browse more venture capital transactions:
Prev: 8/10/2026: ElevTalk venture capital transaction
Next: 8/10/2026: Erebor Bank venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs